Objective
"ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests (3 Rs). ESNATS will address current drug-testing shortcomings: - testing takes place late in the development cycle - animal test systems bear the risk of non-prediction due to inter-species variation - non-ESC assays rely on primary cells or cells of malignant origin that are hard-to-standardise and limited in regard to quantity, homogeneity and genetic diversity - existing assay systems based on primary animal cell lines do not reliably represent the physiological situation ESNATS will develop a battery of toxicity tests using hESC lines subjected to different standardised culture protocols. Tests will cover embryoid bodies in different developmental stages and differentiated derivatives including gamete and neuronal lineages, complemented with test systems for hepatic metabolism. Predictive toxicogenomics and proteomics markers will be identified. The individual tests will be integrated into an ""all-in-one"" test system. To enable future industrial use ESNATS will prepare automating and scaling up of hESC culture. The predictivity, quality and reproducibility of ESNATS will be evaluated in a proof of concept study. ESNATS benefits are to increase safety due to better predictivity of human test systems, to reduce, refine and replace animal tests, to lower testing cost, and to support medium/high throughput testing. ESNATS objectives will be achieved in a 5 year multi-disciplinary collaboration of leading European researchers in alternative testing, toxicology, ESC research, genomics, modelling, and automation. The consortium will also include representatives from regulatory bodies, the pharmaceutical industry and ethical advisors to provide guidance to ensure rapid applicability of the developed tests systems."
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomics
- social sciencessociologyindustrial relationsautomation
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicinetoxicology
Keywords
Call for proposal
FP7-HEALTH-2007-A
See other projects for this call
Funding Scheme
CP-IP - Large-scale integrating projectCoordinator
50937 Koeln
Germany
See on map
Participants (32)
1049 Brussels
See on map
Participation ended
NE1 7RU Newcastle Upon Tyne
1211 Geneve
See on map
44139 Dortmund
See on map
1030 Brussel
See on map
SG8 5WY Royston
See on map
51003 Tartu
See on map
55129 Mainz
See on map
Participation ended
4000 Liege
Participation ended
56024 San Miniato
413 46 Göteborg
See on map
91121 Jerusalem
See on map
78464 Konstanz
See on map
SW1W 9SZ London
See on map
2595 DA Den Haag
See on map
EH8 9YL Edinburgh
See on map
1050 Brussel
See on map
Participation ended
81675 Muenchen
75008 Paris
See on map
Participation ended
WC1N 1AX London
Participation ended
5349 AB Oss
75103 Uppsala
See on map
2500 Valby
See on map
28760 Tres Cantos Madrid
See on map
10589 Berlin
See on map
IV51 9YD Isle Of Skye
See on map
30167 Hannover
See on map
4070 Basel
See on map
26100 Cremona
See on map
UB8 3PH Uxbridge
See on map
72074 Tuebingen
See on map
LS2 7UE Leeds
See on map